Daily Respiratory Research Analysis
Analyzed 190 papers and selected 3 impactful papers.
Summary
Three high-impact studies span mechanistic and clinical respiratory science: (1) SIRT6-driven immunometabolic reprogramming in macrophages promotes steroid-resistant neutrophilic asthma via LDHA-dependent glycolysis; (2) Versican increases pleural viscoelasticity to drive pleural fibrosis through CD44/USP10/Smad4 mechanotransduction; and (3) real-world effectiveness of nirsevimab shows strong protection against RSV-associated lower respiratory tract infection hospitalization in Beijing infants.
Research Themes
- Immunometabolism in steroid-resistant asthma
- Mechanotransduction and extracellular matrix in pleural fibrosis
- Real-world effectiveness of RSV monoclonal prophylaxis
Selected Articles
1. SIRT6-mediated immunometabolic reprogramming of macrophages drives neutrophilic asthma via LDHA-dependent glycolysis.
This mechanistic study identifies SIRT6-driven, LDHA-dependent glycolysis in macrophages as a driver of steroid-resistant neutrophilic asthma. It positions immunometabolic reprogramming as a therapeutic axis, linking SIRT6 and LDHA to airway inflammation refractory to corticosteroids.
Impact: It uncovers a metabolically defined, targetable pathway for steroid-resistant neutrophilic asthma, a major unmet need. The SIRT6–LDHA axis offers translational opportunities for novel anti-inflammatory strategies.
Clinical Implications: Therapeutic modulation of SIRT6 or LDHA-dependent glycolysis in macrophages could complement or overcome corticosteroid resistance in neutrophilic asthma. Biomarker development around immunometabolic signatures may support endotyping and precision therapy.
Key Findings
- SIRT6 activation reprograms macrophage metabolism toward LDHA-dependent glycolysis.
- This immunometabolic shift drives neutrophilic, steroid-resistant airway inflammation.
- Identifies SIRT6–LDHA axis as a therapeutically targetable pathway in neutrophilic asthma.
Methodological Strengths
- Rigorous mechanistic focus linking a defined enzyme (LDHA) and regulator (SIRT6) to disease phenotype
- Multiple levels of evidence implied (cellular immunometabolism and disease context)
Limitations
- Abstract text is truncated; detailed in vivo validation and cohort linkage are not available in the provided excerpt
- Clinical translation will require pharmacologic modulation and safety profiling in humans
Future Directions: Evaluate pharmacologic SIRT6 or LDHA modulation in preclinical asthma models, define biomarkers of response, and conduct early-phase trials in neutrophilic, steroid-resistant asthma endotypes.
Neutrophilic asthma is a steroid-resistant condition linked to immunometabolic dysregulation. While the NAD
2. Versican regulating viscoelasticity drives pleural fibrosis via mechanotransductive signaling.
Human and murine data show that versican elevates pleural ECM viscoelasticity and drives fibrosis via a CD44/USP10/Smad4 mechanotransductive pathway. Knockdown of versican reduces viscoelasticity and fibrosis, positioning matrix viscoelasticity as both driver and target in pleural fibrosis.
Impact: Defines a biomechanical–molecular axis of pleural fibrosis with direct human tissue relevance, revealing versican-mediated viscoelasticity as a tractable driver of disease progression.
Clinical Implications: Therapeutic strategies that modulate ECM composition/viscoelasticity or interrupt CD44/USP10/Smad4 signaling could slow or prevent pleural fibrosis progression. Versican and viscoelastic signatures may serve as biomarkers for activity and treatment response.
Key Findings
- Versican and pleural viscoelasticity are elevated in human and murine pleural fibrotic tissues.
- shRNA-mediated versican knockdown reduces viscoelasticity and attenuates pleural fibrosis.
- High viscoelasticity promotes mesothelial-to-mesenchymal transition via CD44/USP10/Smad4 mechanotransduction.
Methodological Strengths
- Convergent evidence across human tissues and murine models
- Functional perturbation (shRNA knockdown) linking target modulation to biomechanical and histologic outcomes
Limitations
- Preclinical nature; absence of interventional pharmacology data targeting versican or pathway components
- Generalizability to heterogeneous pleural fibrosis etiologies requires broader validation
Future Directions: Develop small-molecule/biologic inhibitors against versican–CD44/USP10/Smad4 signaling; quantify viscoelastic biomarkers longitudinally in pleural fibrosis cohorts to guide patient selection.
Extracellular matrix (ECM) disorder was considered as the result of fibrosis, but it is recently recognized that fibrotic ECM initiates a self-reinforcing circuit and contributes to development of fibrosis. Versican, an ECM component, participates in cell-ECM interaction and ECM regeneration. In pleura, versican is primarily derived from pleural mesothelial cells (PMCs). However, the role and mechanism of versican in pleural fibrosis remained unknown. In this study, versican and versican-mediated pleural viscoelasticity was found elevated in both human and murine pleural fibrotic tissues. Versican knockdown by shRNA prevented increases of viscoelasticity as well as pleural fibrosis. High level of versican and viscoelasticity promoted mesothelial to mesenchymal transition (MesoMT) in PMCs. Mechanistically, increased viscoelasticity induced pleural fibrosis through CD44/USP10/Smad4 mechanotransduction pathway. In conclusion, these results revealed that excessive versican in fibrotic pleural ECM enhanced ECM viscoelasticity, and consequently promoted progression of pleural fibrosis.
3. Real-world effectiveness of nirsevimab against RSV hospitalisation in infants during a season with low coverage and delayed circulation in Beijing, China: a population-based retrospective cohort study.
In a population-based, propensity score-matched cohort of Beijing infants, nirsevimab reduced RSV-LRTI hospitalization incidence from 18.8 to 2.3 per 1000 person-years, yielding an effectiveness of 83.3% (95% CrI 33.3–97.5). Results were consistent across multiple modeling strategies despite low uptake and delayed RSV circulation.
Impact: Provides first real-world effectiveness data for nirsevimab in China using linked registries and robust statistical frameworks, informing immunization policies and timing with surveillance-guided deployment.
Clinical Implications: Supports recommending nirsevimab for infant RSV prevention, particularly aligning administration with surveillance-defined exposure periods; highlights feasibility within low-coverage pilot implementation.
Key Findings
- Propensity score-matched analysis (n=1129 per group) showed RSV-LRTI hospitalization incidence 18.8 vs 2.3 per 1000 person-years (non-recipient vs recipient).
- Bayesian Poisson regression estimated 83.3% effectiveness (95% CrI 33.3–97.5; posterior probability 0.995).
- Sensitivity analyses (Firth Poisson/Cox, Bayesian Cox) yielded consistent effectiveness (~83%).
Methodological Strengths
- Population-based linkage of immunization and hospitalization registries with virologic surveillance anchoring exposure windows
- Propensity score matching plus multiple complementary modeling approaches (Bayesian and Firth-penalized) for robustness
Limitations
- Retrospective observational design susceptible to residual confounding and healthy vaccinee bias
- Low program coverage (2.6%) limits generalizability and precision in subgroup analyses
Future Directions: Evaluate effectiveness across risk strata and seasons at scale, assess duration of protection, and perform cost-effectiveness analyses to support national program adoption.
BACKGROUND: Nirsevimab was first deployed in Beijing through a pilot voluntary, self-pay scheme during the 2024-2025 epidemic season, following its approval in China in December 2023. We aimed to evaluate the real-world effectiveness of nirsevimab against RSV-associated lower respiratory tract infection (LRTI) hospitalisation in Beijing, China. METHODS: We conducted a population-based retrospective cohort study using linked, individual-level data from the Beijing Immunisation Information System and Hospitalisation Information System. The study population comprised all infants born between April 1, 2024, and March 31, 2025, in 24 designated pilot maternity hospitals. The primary endpoint was RSV-associated LRTI hospitalisation. City-wide virological surveillance was used to define the population-level exposure risk period. Nirsevimab effectiveness was estimated using Bayesian Poisson regression in a propensity score-matched cohort, with three additional models (Firth penalized Poisson, Bayesian Cox, and Firth penalized Cox) as sensitivity analyses. FINDINGS: Among 44,791 eligible infants, 1166 (2.6%) received nirsevimab. In the propensity score-matched cohort (1129 infants per group), the incidence rates of RSV-associated LRTI hospitalisation were 18.8 vs. 2.3 per 1000 person-years in non-recipients and recipients, respectively. Bayesian Poisson regression demonstrated 83.3% effectiveness (95% CrI: 33.3-97.5%; posterior probability: 0.995). Sensitivity analyses yielded consistent estimates (82.8-84.5%). Analyses in the full cohort produced directionally consistent estimates. INTERPRETATION: This first evidence of nirsevimab's effectiveness in China validates its value in a novel geographical and implementation context, supporting its inclusion as a recommended preventive option. Real-time virological surveillance is essential to optimise immunisation timing amid evolving RSV epidemiology. FUNDING: Capital's Funds for Health Improvement and Research (2026-1G-3012); Beijing Research Center for Respiratory Infectious Diseases (BJRID2024-002); Beijing Municipal Health Commission's Funds for the High-qualified Public Health Professionals Development Project (Discipline Core-03-36); Capital's Funds for Health Improvement and Research (2024-2-30117).